Science & Enterprise subscription

Follow us on Twitter

  • New post on Science and Enterprise: Microrobot Swarm Breaks Up Bacterial Biofilms #Science #Business
    about 28 mins ago
  • After Pentagon Ends Contract, Top-Secret Scientists Group Vows To Carry On ... "We're very…
    about 14 hours ago
  • Hospital, academic, and industry researchers devised automated techniques including artificial intelligence to shar…
    about 18 hours ago
  • New post on Science and Enterprise: A.I. Speeds Infant Genetic Disease Diagnostics #Science #Business
    about 18 hours ago
  • A neuroscience lab created a virtual speech-generating vocal system that produces natural sounding human speech by…
    about 23 hours ago

Please share Science & Enterprise

Follow by Email
Visit Us

Cancer Diagnostics Company Gains $5M in Early Round Funds

10, 20, and 50 dollar bills (


On-Q-ity in Waltham, Massachusetts, a developer of cancer diagnostics technology, says it has added $5 million in series B financing, the second round of funding after initial start-up. Participants in the round are Mohr Davidow Ventures, Atlas Ventures, and Physic Ventures, all of which are current investors in the company.

On-Q-Ty — short for Oncology + Quality + Clarity — develops personalized cancer diagnostics based on circulating tumor cells (CTCs), cancer cells that have broken away from the main tumor and spread through the body in the bloodstream. If CTCs become embedded elsewhere in the body, new cancers can form.

CTCs that break away from the tumor offer a way of diagnosing the current make up of the tumor that can alter its composition in response to treatment. On-Q-Ty’s technology captures, analyzes, and classifies CTCs in blood to identify CTCs with a variety of alterations in DNA, RNA or proteins. Researchers will be able to use the On-Q-ity technology to guide targeted therapies, monitor treatments, and detect cancer recurrence.

The company also announced the appointment of Michael Stocum as its new CEO. Stocum is president of Personalized Medicine Partners, a company providing services to biotechnology and diagnostics businesses.

On-Q-Ty reported on tests of its C5 chip product in July 2011 at a meeting of the American Association of Clinical Chemistry. The tests used cultured tumor cells added to normal human blood, as well as samples of blood from patients with advanced cancers. The findings showed the chip captured and identified a high percentage of the target cells, including in 97 percent of samples with cultured tumor cells.

Read more:

*     *     *

Please share Science & Enterprise ...

1 comment to Cancer Diagnostics Company Gains $5M in Early Round Funds